The estimated Net Worth of Robert E. George is at least $35.2 ezer dollars as of 26 December 2023. Robert George owns over 14,493 units of Moleculin Biotech Inc stock worth over $35,184 and over the last 8 years Robert sold MBRX stock worth over $0.
Robert has made over 2 trades of the Moleculin Biotech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Robert bought 14,493 units of MBRX stock worth $10,000 on 26 December 2023.
The largest trade Robert's ever made was buying 14,493 units of Moleculin Biotech Inc stock on 26 December 2023 worth over $10,000. On average, Robert trades about 1,408 units every 221 days since 2016. As of 26 December 2023 Robert still owns at least 14,660 units of Moleculin Biotech Inc stock.
You can see the complete history of Robert George stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON, TX, 77007.
Over the last 8 years, insiders at Moleculin Biotech Inc have traded over $340,000 worth of Moleculin Biotech Inc stock and bought 433,338 units worth $371,310 . The most active insiders traders include Walter V Klemp, John M Climaco és Waldemar Priebe. On average, Moleculin Biotech Inc executives and independent directors trade stock every 75 days with the average trade being worth of $69,293. The most recent stock trade was executed by Walter V Klemp on 2 July 2024, trading 982 units of MBRX stock currently worth $2,357.
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
Moleculin Biotech Inc executives and other stock owners filed with the SEC include: